Abstract
Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.
| Original language | English |
|---|---|
| Pages (from-to) | 253-261 |
| Number of pages | 9 |
| Journal | Clinical Immunology and Immunopathology |
| Volume | 47 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1988 |
Fingerprint
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
- Pathology and Forensic Medicine
Cite this
Thymostimulin treatment in AIDS-related complex. / Palmisano, Lucia; Chisesi, Teodoro; Galli, Massimo; Gritti, Francesco M.; Ielasi, Giuseppe; Lazzarin, Adriano; Mezzaroma, Ivano; Moroni, Mauro; Raise, Enzo; Vaglia, Alberto; Aiuti, Fernando.
In: Clinical Immunology and Immunopathology, Vol. 47, No. 3, 1988, p. 253-261.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Thymostimulin treatment in AIDS-related complex
AU - Palmisano, Lucia
AU - Chisesi, Teodoro
AU - Galli, Massimo
AU - Gritti, Francesco M.
AU - Ielasi, Giuseppe
AU - Lazzarin, Adriano
AU - Mezzaroma, Ivano
AU - Moroni, Mauro
AU - Raise, Enzo
AU - Vaglia, Alberto
AU - Aiuti, Fernando
PY - 1988
Y1 - 1988
N2 - Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.
AB - Thirty-four patients with AIDS-related complex (ARC) were treated for 6 months with thymostimulin, a thymic hormone. Clinical and immunological findings after a 1-year follow-up were compared with those in 24 age- and sex-matched controls receiving no immunotherapy. Statistical evaluation after 6 and 12 months showed significant differences in the two groups. The thymostimulin-treated group had higher leukocyte and lymphocyte counts, more positivity in intradermal tests with multiple recall antigens, and less lymphadenopathy and weight loss. The number of OKT3+ and OKT4+ lymphocytes decreased significantly in the control group, but did not change in the thymostimulin-treated patients. Finally, after 18 months of follow-up, no progression to AIDS was seen among the treated subjects, whereas 3 of the controls developed the disease. We conclude that thymostimulin, alone or in combination with antiviral drugs, may be helpful in the management of ARC patients.
UR - http://www.scopus.com/inward/record.url?scp=0023891399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023891399&partnerID=8YFLogxK
U2 - 10.1016/S0090-1229(88)80003-5
DO - 10.1016/S0090-1229(88)80003-5
M3 - Article
C2 - 3259480
AN - SCOPUS:0023891399
VL - 47
SP - 253
EP - 261
JO - Clinical Immunology and Immunopathology
JF - Clinical Immunology and Immunopathology
SN - 0090-1229
IS - 3
ER -